Related Experiment Video
Updated: Jan 17, 2026
10:21
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
10.6K
Kaempferol Inhibits Myocardial Fibrosis by Downregulating FVII
Ming Zhang1, Zhengbo Zhu2, Qian Zhou3
1Anhui Medical College.
Critical Reviews in Eukaryotic Gene Expression
|September 19, 2025
Summary
Kaempferol (KMP) effectively treats myocardial fibrosis by improving heart function and reducing inflammation. KMP downregulates coagulation factor VII (FVII), offering a potential therapy for heart conditions.
Area of Science:
- Cardiovascular Research
- Pharmacology
- Biochemistry
Background:
- Myocardial fibrosis is a key factor in heart failure progression.
- Kaempferol (KMP), a natural flavonoid, possesses antioxidant and anti-inflammatory properties.
- Understanding KMP's role in mitigating myocardial fibrosis is crucial.
Purpose of the Study:
- To investigate the therapeutic effects of Kaempferol (KMP) on isoproterenol-induced myocardial fibrosis.
- To elucidate the molecular mechanisms underlying KMP's cardioprotective actions.
Main Methods:
- Myocardial fibrosis model induced by isoproterenol injection in mice.
- Cardiac function assessed via echocardiography.
- Histological analysis (Masson, Sirius red), immunohistochemistry (α-SMA, Collagen III), RT-qPCR, ELISA, and Western blot were employed.
Main Results:
- KMP treatment significantly improved cardiac function and suppressed myocardial fibrosis.
- KMP decreased fibrosis-related gene expression and attenuated inflammation.
- KMP inhibited the overexpression of coagulation factor VII (FVII), which is linked to fibrosis and inflammation.
Conclusions:
- Kaempferol (KMP) demonstrates protective effects against myocardial fibrosis.
- KMP exerts its benefits by downregulating coagulation factor VII (FVII).
- KMP presents a promising therapeutic candidate for treating myocardial fibrosis and related cardiovascular diseases.
More Related Videos
09:16Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
7.7K
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
4.3K
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
414
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
414
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
942
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
942
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
461
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
461
01:29Heart Failure II: Pathophysiology
734
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
734
01:21Myocarditis I: Introduction
374
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
374
01:30Cardiomyopathy II: Dilated Cardiomyopathy
480
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
480